Benzinga.com

AstraZeneca's Multi-Billion Dollar Cancer Drug Tagrisso Improves Overall Survival In Patients With Advanced Lung Cancer

On Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial of Tagrisso (osimertinib) with the addition of pemetrexed ...
MM&M

In AstraZeneca’s DTC spot, Tagrisso breathes new life into lung cancer treatment

The Tagrisso train rolls on for AstraZeneca. The British pharma giant’s oncology unit recently launched its first direct-to-consumer US commercial supporting Tagrisso (osimertinib) to help lung cancer ...
Morningstar

TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR ...

Positive results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based ...
Nasdaq

AstraZeneca's TAGRISSO Combo Delivers Survival Advantage In EGFRm NSCLC Phase III Trial

(RTTNews) - AstraZeneca (AZN) announced positive results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial, demonstrating that TAGRISSO (osimertinib) combined with ...